DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Zydus Lifesciences Limited — Investor Presentation

NSE 1 hr ago·4 Nov 2026, 7:05 am

Zydus Lifesciences

Zydus Lifesciences has submitted its investor presentation to the stock exchanges, a standard disclosure that outlines the company's future strategy and financial outlook. This document typically includes management's views on business performance, upcoming product launches, and long-term growth plans.

For investors, this update is significant as it provides transparency into the company's direction. It helps shareholders understand how management plans to navigate the competitive pharmaceutical landscape and execute its vision for the future.

Moving forward, investors should focus on the specific details regarding product pipelines, revenue guidance, and operational efficiency mentioned in the presentation. Monitoring these key areas will be essential to gauge the company's potential for sustained growth.